A novel cancer therapeutic using thrombospondin 1 in dendritic cells

Molecular Therapy

Volumn 22, Issue 2, 2014, Pages 292-302

  Weng, Tzu Yang ^a   Huang, Shih Shien ^a   Yen, Meng Chi ^a,b   Lin, Chi Chen ^a   Chen, Yi Ling ^c   Lin, Chiu Mei ^c   Chen, Wei Ching ^a   Wang, Chih Yang ^a   Chang, Jang Yang ^e   Lai, Ming Derg ^a,d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 12; NEU DNA VACCINE; SHORT HAIRPIN RNA; THROMBOSPONDIN 1; THROMBOSPONDIN 2; UNCLASSIFIED DRUG; CANCER VACCINE; SMALL INTERFERING RNA; THROMBOSPONDIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BLADDER TUMOR; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENE SILENCING; LUNG TUMOR; LYMPH NODE; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PROTEIN TARGETING; SURVIVAL RATE; T CELL DEPLETION; TUMOR CELL; ANIMAL; DEFICIENCY; DISEASE MODEL; GENE THERAPY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MORTALITY; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SKIN; TUMOR CELL LINE;

MUS;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GENE SILENCING; GENETIC THERAPY; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RNA, SMALL INTERFERING; SKIN; THROMBOSPONDIN 1; THROMBOSPONDINS; VACCINES, DNA;

EID: 84895904317     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.236     Document Type: Article

References (48)

1. Akbari, O, DeKruyff, RH and Umetsu, DT (2001). Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2: 725-731.
2. Quaratino, S, Duddy, LP and Londei, M (2000). Fully competent dendritic cells as inducers of T cell anergy in autoimmunity. Proc Natl Acad Sci USA 97: 10911-10916.
3. Rutella, S, Danese, S and Leone, G (2006). Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108: 1435-1440.
4. Yamazaki, S, Iyoda, T, Tarbell, K, Olson, K, Velinzon, K, Inaba, K et al. (2003). Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 198: 235-247.
5. Munn, DH, Sharma, MD, Hou, D, Baban, B, Lee, JR, Antonia, SJ et al. (2004). Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumordraining lymph nodes. J Clin Invest 114: 280-290.
6. Makala, LH (2012). The role of indoleamine 2, 3 dioxygenase in regulating host immunity to leishmania infection. J Biomed Sci 19: 5.
7. Zhang, X, Galardi, E, Duquette, M, Lawler, J and Parangi, S (2005). Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res 11: 5622-5630.
8. Zhang, X and Lawler, J (2007). Thrombospondin-based antiangiogenic therapy. Microvasc Res 74: 90-99.
9. Chen, H, Herndon, ME and Lawler, J (2000). The cell biology of thrombospondin-1. Matrix Biol 19: 597-614.
10. Dameron, KM, Volpert, OV, Tainsky, MA and Bouck, N (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584.
11. Iruela-Arispe, ML, Bornstein, P and Sage, H (1991). Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA 88: 5026-5030.
12. Martin-Manso, G, Galli, S, Ridnour, LA, Tsokos, M, Wink, DA and Roberts, DD (2008). Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res 68: 7090-7099.
13. Ebbinghaus, S, Hussain, M, Tannir, N, Gordon, M, Desai, AA, Knight, RA et al. (2007). Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 13(22 Pt 1): 6689-6695.
14. Markovic, SN, Suman, VJ, Rao, RA, Ingle, JN, Kaur, JS, Erickson, LA et al. (2007). A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 30: 303-309.
15. Grimbert, P, Bouguermouh, S, Baba, N, Nakajima, T, Allakhverdi, Z, Braun, D et al. (2006). Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25- T cells in response to inflammation. J Immunol 177: 3534-3541.
16. Letterio, JJ and Roberts, AB (1998). Regulation of immune responses by TGF-beta. Annu Rev Immunol 16: 137-161.
17. Murphy-Ullrich, JE and Poczatek, M (2000). Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 11: 59-69.
18. Narizhneva, NV, Razorenova, OV, Podrez, EA, Chen, J, Chandrasekharan, UM, DiCorleto, PE et al. (2005). Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J 19: 1158-1160.
19. Schultz-Cherry, S and Murphy-Ullrich, JE (1993). Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol 122: 923-932.
20. Young, GD and Murphy-Ullrich, JE (2004). The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem 279: 47633-47642.
21. Doyen, V, Rubio, M, Braun, D, Nakajima, T, Abe, J, Saito, H et al. (2003). Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. J Exp Med 198: 1277-1283.
22. Marteau, F, Gonzalez, NS, Communi, D, Goldman, M, Boeynaems, JM and Communi, D (2005). Thrombospondin-1 and indoleamine 2,3-dioxygenase are major targets of extracellular ATP in human dendritic cells. Blood 106: 3860-3866.
23. Melief, CJ (2008). Cancer immunotherapy by dendritic cells. Immunity 29: 372-383.
24. Condon, C, Watkins, SC, Celluzzi, CM, Thompson, K and Falo, LD Jr (1996). DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2: 1122-1128.
25. Lin, CC, Yen, MC, Lin, CM, Huang, SS, Yang, HJ, Chow, NH et al. (2008). Delivery of noncarrier naked DNA vaccine into the skin by supersonic flow induces a polarized T helper type 1 immune response to cancer. J Gene Med 10: 679-689.
26. Porgador, A, Irvine, KR, Iwasaki, A, Barber, BH, Restifo, NP and Germain, RN (1998). Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 188: 1075-1082.
27. Provinciali, M, Barucca, A, Pierpaoli, E, Orlando, F, Pierpaoli, S and Smorlesi, A (2012). In vivo electroporation restores the low effectiveness of DNA vaccination against HER- 2/neu in aging. Cancer Immunol Immunother 61: 363-371.
28. Kim, TW, Lee, JH, He, L, Boyd, DA, Hardwick, JM, Hung, CF et al. (2005). Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 65: 309-316.
29. Yen, MC, Lin, CC, Chen, YL, Huang, SS, Yang, HJ, Chang, CP et al. (2009). A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res 15: 641-649.
30. Liu, C, Lou, Y, Lizée, G, Qin, H, Liu, S, Rabinovich, B et al. (2008). Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 118: 1165-1175.
31. Lin, CC, Chou, CW, Shiau, AL, Tu, CF, Ko, TM, Chen, YL et al. (2004). Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther 10: 290-301.
32. Hodi, FS, O'Day, SJ, McDermott, DF, Weber, RW, Sosman, JA, Haanen, JB et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
33. Kantoff, PW, Higano, CS, Shore, ND, Berger, ER, Small, EJ, Penson, DF et al.; IMPACT Study Investigators. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
34. Drutman, SB and Trombetta, ES (2010). Dendritic cells continue to capture and present antigens after maturation in vivo. J Immunol 185: 2140-2146.
35. Allan, RS, Waithman, J, Bedoui, S, Jones, CM, Villadangos, JA, Zhan, Y et al. (2006). Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 25: 153-162.
36. Adams, JC and Lawler, J (2004). The thrombospondins. Int J Biochem Cell Biol 36: 961-968.
37. Lamy, L, Foussat, A, Brown, EJ, Bornstein, P, Ticchioni, M and Bernard, A (2007). Interactions between CD47 and thrombospondin reduce inflammation. J Immunol 178: 5930-5939.
38. Futagami, Y, Sugita, S, Vega, J, Ishida, K, Takase, H, Maruyama, K et al. (2007). Role of thrombospondin-1 in T cell response to ocular pigment epithelial cells. J Immunol 178: 6994-7005.
39. Willingham, SB, Volkmer, JP, Gentles, AJ, Sahoo, D, Dalerba, P, Mitra, SS et al. (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109: 6662-6667.
40. Bocci, G, Francia, G, Man, S, Lawler, J and Kerbel, RS (2003). Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100: 12917-12922.
41. Punekar, S, Zak, S, Kalter, VG, Dobransky, L, Punekar, I, Lawler, JW et al. (2008). Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology 75: 9-21.
42. Opitz, CA, Litzenburger, UM, Sahm, F, Ott, M, Tritschler, I, Trump, S et al. (2011). An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478: 197-203.
43. Mittal, R, Gonzalez-Gomez, I and Prasadarao, NV (2010). Escherichia coli K1 promotes the ligation of CD47 with thrombospondin-1 to prevent the maturation of dendritic cells in the pathogenesis of neonatal meningitis. J Immunol 185: 2998-3006.
44. Lu, TJ, Lai, WY, Huang, CY, Hsieh, WJ, Yu, JS, Hsieh, YJ et al. (2006). Inhibition of cell migration by autophosphorylated mammalian sterile 20-like kinase 3 (MST3) involves paxillin and protein-tyrosine phosphatase-PEST. J Biol Chem 281: 38405-38417.
45. Inaba, K, Inaba, M, Romani, N, Aya, H, Deguchi, M, Ikehara, S et al. (1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693-1702.
46. Herber, DL, Cao, W, Nefedova, Y, Novitskiy, SV, Nagaraj, S, Tyurin, VA et al. (2010). Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 16: 880-886.
47. Olerud, J, Johansson, M, Lawler, J, Welsh, N and Carlsson, PO (2008). Improved vascular engraftment and graft function after inhibition of the angiostatic factor thrombospondin-1 in mouse pancreatic islets. Diabetes 57: 1870-1877.
48. Huang, TT, Yen, MC, Lin, CC, Weng, TY, Chen, YL, Lin, CM et al. (2011). Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer. Cancer Sci 102: 2214-2220.